FDA Defends Its Line Of Communication As Lifecore Revamps MDR Procedures
This article was originally published in The Gray Sheet
Executive Summary
Lifecore Biomedical had sufficient opportunity to obtain FDA guidance on medical device reporting (MDR) for theIntergel adhesion prevention solution, despite the firm's claims to the contrary, the agency maintains in a Dec. 1 letter
You may also be interested in...
Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
Lifecore Biomedical's efforts to bring its Intergel adhesion prevention solution back to the U.S. market may be slowed by a recent warning letter citing failure to report adverse events to FDA in a timely manner
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.